摘要目的 评价国内2018年发布的“肺血栓栓塞症诊治与预防指南”的质量,为今后更新和制定我国临床实践指南提供借鉴和参考.方法 利用国际公认的指南质量评价工具AGREEⅡ(appraisal of guidelines for research and evaluationⅡ)对我国2018年发布的“肺血栓栓塞症诊治与预防指南”进行质量评价.AGREEⅡ总共包含6个领域共23个条目和2个总体评估条目,每个条目得分为1～7分,综合考虑所有领域和条目来评估指南的质量.结果该指南AGREEⅡ六个领域中“范围和目的”得分76.4％、“参与人员”得分55.6％、“制定的严谨性”得分78.1％、“表达的明晰性”得分83.3％、“应用性”得分55.2％、“编辑独立性”得分66.7％.该指南在临床推荐使用.在101条推荐中,高、中、低级证据分别占7条(6.9％)、31条(30.7％)和63条(62.4％).结论 国内2018年发布的“肺血栓栓塞症诊治与预防指南”的方法学质量整体较高但证据级别不高,得分较低的“参与人员”和“应用性”两个领域仍需加强,特别是应纳入相应的经济学研究证据并进一步重视患者及公众的利益和偏好.

abstractsObjective To assess the quality of the clinical practice guideline for diagnosis,treatment and prevention of pulmonary thromboembolism,2018 in China,providing the references for updating and developing clinical practice guidelines of this field in the future.Methods The quality of the clinical practice guideline for diagnosis,treatment and prevention of pulmonary thromboembolism,2018 in China was assessed using the internationally recognized instrument Appraisal of Guidelines for Research and Evaluation Ⅱ (AGREE Ⅱ).AGREE Ⅱ instrument consisted of 23 items in six domains,followed by two overall assessment items.Each item was scored from 1 to 7.The final overall guideline quality considered all domain items.Results The scores of the six AGREE Ⅱ domains were:Scope and purpose 76.4％,Stakeholder involvement 55.6％,Rigor of development 78.1％,Clarity and presentation 83.3％,Applicability 55.2％,and Editorial independence 66.7％.The guideline was recommended for clinical use.Among the 101 recommendations,recommendations based on Levels High,Moderate and Low evidence accounted for 7 (6.9％),31 (30.7％) and 63 (62.4％),respectively.Conclusion The methodological quality of the clinical practice guideline for diagnosis,treatment and prevention of pulmonary thromboembolism,2018 in China was great,but the levels of evidence were not high.More efforts were urgently required to improve in Stakeholder involvement and applicability.Especially corresponding economic research evidence,as well as preferences of patients and the public should be considered in the future development of clinical practice guidelines.